Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18863174 | 0.85 | FAAH (0.42) | FAAHCAMK2ACCR5SRD5A1TP53 | |
| SCHEMBL2439490 | 0.85 | GHSR (0.47) | CCR5 | |
| SCHEMBL2436113 | 0.85 | GHSR (0.47) | CCR5 | |
| SCHEMBL29250519 | 0.84 | CASP6 (0.42) | FAAHMTNR1BMTNR1ACAMK2ACCR5 | |
| SCHEMBL3682639 | 0.83 | CCR5 (0.55) | FAAHMTNR1BMTNR1ACAMK2ACCR5 | |
| SCHEMBL30508342 | 0.82 | FNTA (0.49) | FAAHMTNR1BMTNR1A | |
| SCHEMBL2571557 | 0.82 | FNTA (0.49) | FAAHMTNR1BMTNR1A | |
| SCHEMBL2571280 | 0.81 | SRD5A1 (0.48) | MTNR1BMTNR1ACCR5SRD5A1GPR84 | |
| SCHEMBL2571011 | 0.81 | SRD5A1 (0.48) | MTNR1BMTNR1ACCR5SRD5A1GPR84 | |
| SCHEMBL2572769 | 0.81 | SRD5A1 (0.48) | MTNR1BMTNR1ACCR5SRD5A1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385035-B1 | PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR | HARBIN GLORIA PHARMACEUTICALS CO LTD (CN) | 2014-06-25 | — | — | EP | disclosed |
| US-8703771-B2 | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor | HARBIN GLORIA PHARMACEUTICALS CO., LTD. (CN) | 2014-04-22 | — | — | US | disclosed |
| US-20110319420-A1 | PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR | HARBIN GLORIA PHARMACEUTICALS CO., LTD (CN) | 2011-12-29 | — | — | US | disclosed |
| EP-2385035-A1 | PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS THEIR PHARMACEUTICAL COMPOSITIONS CONTAING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR | Harbin Gloria Pharmaceuticals Co., Ltd. (CN) | 2011-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319420-A1 | PREPARATION METHOD OF DIHYDROINDENE AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THEREOF AND USE AS PROTEIN KINASES INHIBITOR | KIT, ABL1, ABL2 | FAAH 2172/4885MTNR1B 4821/4885MTNR1A 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.